By Tonya M. Esposito and Renee B. Appel
Seyfarth Synopsis: In its largest mass enforcement action involving cannabidiol (CBD) yet, the U.S. Food & Drug Administration (FDA) announced on November 25 the issuance of 15 warning letters to various companies for illegally selling products containing CBD. In addition to the letters, the FDA published a revised Consumer Update detailing
Continue Reading FDA Stresses CBD Safety Concerns in 15 Warning Letters and Revised Consumer Update
By Jennifer L. Mora, Adam R. Young, and Craig B. Simonsen
Seyfarth Synopsis: The Western District of New York, in Horn v. Medical Marijuana, Inc., et al., issued an initial procedural order last week in a case where the plaintiff’s purchase and use of the defendant products resulted in a failed drug test that resulted in his
Continue Reading CBD Lawsuit Reflects Trucker Termination for THC Tainted Drug Products
By Tonya M. Esposito, Renee B. Appel, and Jonathan Huie
Seyfarth Synopsis: CBD is “thriving” in the current regulatory environment, but is it doing so illegally?
As former U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb opined last week, “the CBD craze is getting out of hand. The FDA needs to act.” Since the passage
Continue Reading CBD is Everywhere – But Where Does the FDA Stand?
Seyfarth Synopsis: The federal Drug Enforcement Agency (DEA) recently announced that drugs that include CBD (cannabidiol) with less than 0.1% of THC (tetrahydrocannabinols) are now considered Schedule V drugs provided they are approved by the federal Food and Drug Administration (FDA). The move marked the first time the DEA removed any form of cannabis from
Continue Reading The Stoned Age: What the CBD Craze Means for Employers and Their Substance Abuse Policies